Clinical Trials
6 trialsNCT01946477 2026-05-22
POM MM 014
Celgene
Phase 2 Completed
NCT06429150 2026-04-24
Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma
Shenzhen Geno-Immune Medical Institute
Phase 1/2 Recruiting
NCT06435910 2026-04-24
Engineered Dendritic Cell Vaccines for Multiple Myeloma
Shenzhen Geno-Immune Medical Institute
Phase 1 Recruiting
NCT03031730 2026-02-10
Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma
National Cancer Institute (NCI)
Phase 1 Terminated
NCT04174196 2025-12-02
A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT02136134 2025-08-29
Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Phase 3 Completed